Document:

EX-10.1

 Exhibit 10.1 

AMENDMENT TO 
 THE CHOICE
HOTELS INTERNATIONAL, INC. 
 2006 LONG-TERM INCENTIVE PLAN 

The 2006 Long-Term Incentive Plan, as amended (the “Plan”) is hereby amended, effective February 27, 2015, as follows: 

A. Section 1.02 is hereby deleted and replaced with the following: 

“Effective Date and Duration of Plan. Unless terminated earlier by the Board, this Plan is effective until February 13, 2018.
Any Awards that are made under the Plan prior to the termination date shall continue in effect in accordance with the terms of the Agreement after that date.” 

B. Section 9.04(d) is hereby deleted and replaced with the following: 

“(d) To the extent consistent with Section 162(m) of the Code, the Committee (i) may appropriately establish performance
criteria that either disregards or takes into account the effects of charges for restructurings, discontinued operations, extraordinary items and all items of gain, loss or expense determined to be extraordinary or unusual in nature or related to
the disposal of a segment of a business or related to a change in accounting principle all as determined in accordance with standards established by opinion No. 30 of the Accounting Principles Board or other applicable or successor accounting
provisions, as well as the cumulative effect of accounting changes, in each case as determined in accordance with generally accepted accounting principles or identified in the Company’s financial statements or notes to the financial statements,
and (ii) may appropriately establish performance criteria that either includes or excludes gains and losses related to any of the following events that occurs during a performance period: (A) the sale of assets, (B) litigation,
claims, judgments or settlements, (C) the effect of changes in tax law or other such laws or provisions affecting reported results, (D) accruals for reorganization and restructuring programs, (E) accruals of any amounts for payment
under this Plan or any other compensation arrangement maintained by the Company, and (F) investments in or expenses related to new lines of business or non-core business initiatives that were unbudgeted at the time the performance criteria was
established.” 
 Except as set forth in this Amendment, the Plan shall remain unchanged and shall continue in full force and effect.Exhibit 10.1

 

 

VIA EMAIL ONLY

 

April 20, 2015

 

Thomas Liquard

57 Lonsdale Avenue

Hampton East, VIC 3188

Australia

 

Re: Director Offer Letter

 

Dear Mr. Thomas:

 

This letter shall constitute an
agreement (“Agreement”) between you and PharmaCyte Biotech (“Company”) and contains all the terms
and conditions relating to your service to the Company as a member of our Board of Directors (“Board”).

 

1.            Term.
This Agreement will become effective as of April 1, 2015 and continue until your resignation or removal, or until your successor
is duly elected and qualified. Your position will be subject to re-election each year at the annual shareholders’ meeting
and, upon re-election, the terms and provisions of this Agreement shall remain in full force and effect.

 

		2.	Services.

 

2.1.
Duties. You shall render services as a member of the Board in accordance with high professional and ethical
standards and in accordance with all applicable laws, rules and regulations pertaining to your performance under this
Agreement. You shall use your best efforts to attend all meetings of the Board called from time to time, either in-person or
by telephone. You will serve as the Chairman of the Audit Committee of the Board and shall use your best efforts to attend
such number of meetings of the Audit Committee as required by its members pursuant to the Audit Committee Charter or as may
be called from time to time. As an independent director, you may also be required to attend meetings with the other
independent directors without the presence of the Company’s officers and non-independent directors. The services
described in this Section 2.1 shall hereinafter be referred to as your “Duties.”

 

2.2. Reporting.
While this Agreement is in effect, you shall immediately advise the Company if: (i) you know, have reason to know, or believe,
that you are no longer independent; and (ii) you serve on an audit committee of any other public company.

 

 

 

 

 

12510 Prosperity Drive | Suite 310 | Silver
Spring | Maryland 20904-1643

Office: 917.595.2850 | Fax: 917.595.2851
| Mobile: 917.595.2852 | kwaggoner@PharmaCyteBiotech.com

 

    	1

    	 

    

 

3.Services
for Others. You shall be free to represent or perform services for other persons during the term of this
Agreement. You represent, however, that you do not presently perform and do not intend to perform, during the term of this
Agreement, similar duties, consulting or performing other services for companies whose businesses are or would be in any way
competitive with the Company (except for companies previously disclosed by you to the Company in writing). Should you propose
to perform similar duties, consulting, or other services for any such company, you agree to notify the Company in writing in
advance (specifying the name of the organization for whom you propose to perform such services) and to provide information to
the Company sufficient to allow it to determine if the performance of such services would conflict with your Duties.

 

		4.	Compensation.

 

4.1.          Cash.
The Company will pay you cash compensation of $9,000 per quarter, payable in advance and pro-rated for periods of less than a quarter.
You shall be reimbursed for reasonable expenses documented and incurred by you in connection with the performance of your Duties
(including travel expenses for meetings you attend in-person).

 

4.2.          Stock
Option Grant. Concurrently with your appointment to the Board, you will be issued a five year option to purchase 250,000
shares of the Company’s common stock at an exercise price equal to the fair market value of the Company’s common stock
on the date of grant (“Option”). The Option will be fully vested as of the date of grant. The Company will issue
you an option agreement in the Company’s standard form to evidence the Option.

 

4.3.          Service
on Board Committee(s). Should you be named to any additional committee of the Board, the Compensation Committee of the
Board will determine any additional compensation, if any, that you will receive for serving on such committee.

4.4.          Taxes.
You are solely responsible for taxes arising out of any compensation paid by the Company
to you under this Agreement, and you understand that you will be issued a U.S. Treasury form 1099 for any compensation paid to
you by the Company. The Company will comply with any tax or withholding obligations as required by applicable law from time to
time in connection with this Agreement.

 

5.             D&O
Insurance Policy. During the term of this Agreement, the Company shall include you as
an insured under its existing director’s and officer’s insurance policy, with coverage determined annually by the Company
and the Board. 

 

6.             No
Assignment. Because of the personal nature of the services to be rendered by you, this Agreement may not be assigned by
you without the prior written consent of the Company.

 

7.             Confidential
Information; Non-Disclosure. In consideration of your access to the premises of the Company and/or you access to certain
confidential information of the Company, you hereby represent and agree as follows:

 

 

    	2

    	 

    

  

7.1.          Definition.
For purposes of this Agreement, the term “Confidential Information” means:

 

a.              Any
information that the Company possesses that has been created, discovered, or developed by or for the Company and that has or could
have commercial value or utility in the business in which the Company is engaged;

 

b.              Any
information provided to the Board at or for meetings of the Board, and any information relating to proceedings of the Board; or

 

c.              Any
information that is related to the business of the Company and is generally not known by non-Company personnel.

 

7.2.           Exclusions.
Notwithstanding the foregoing, the term Confidential Information does not include:

 

a.              Any
information that becomes generally available to the public, other than as a result of a breach of this Agreement or any other agreement
requiring confidentiality between the Company and you;

 

b.              Information
received from a third party in rightful possession of such information who is not restricted from disclosing such information;
and

 

c.              Information
known by you prior to receipt of such information from the Company, which prior knowledge can be documented.

 

7.3.          Documents.
You agree that, without the express prior written consent of the Company, you will not remove from the Company's premises any
notes, formulas, programs, data, records, machines, or any other documents or items that in any manner contain or constitute Confidential
Information, nor will you make reproductions or copies of the same. In the event you receive any such documents or items by personal
delivery from any duly designated or authorized personnel of the Company, you shall be deemed to have received the express written
consent of the Company. In the event that you receive any such documents or items, other than through personal delivery as described
in the preceding sentence, you agree to inform the Company promptly of your possession of such documents or items. You shall promptly
return any such documents or items, along with any reproductions or copies to the Company upon the Company's demand, upon termination
of this Agreement, or upon your termination or Resignation, as defined in Section 8 below.

 

7.4.          No
Disclosure. You agree that you will hold in trust and confidence all Confidential Information and will not disclose to
others, directly or indirectly, any Confidential Information or anything relating to such information without the prior written
consent of the Company, except as maybe necessary in the course of your relationship with the Company. You further agree that you
will not use any Confidential Information other than in connection with your service as a member of the Board without the prior
written consent of the Company. The provisions of this Section 7.4 shall survive termination of this Agreement.

 

    	3

    	 

    

 

8.      Termination
and Resignation. Your membership on the Company’s Board may be terminated for any or no reason except as
provided in the Company’s organizational documents or pursuant to applicable law. You may also terminate your
membership on the Board for any or no reason, by delivering your written notice of resignation to the Company
(“Resignation”). Such Resignation shall be effective on the later of the date of its delivery or the date
specified in the Resignation. Upon the effective date of the termination or Resignation, your right to compensation hereunder
will terminate, subject to the Company's obligations to pay you any compensation that you have already earned and to
reimburse you for approved expenses already incurred in connection with your performance of your Duties as of the effective
date of such termination or Resignation.

 

9.      Not
an Employee. Nothing in this Agreement shall be construed as a contract of employment/engagement between you and the Company
or as a commitment on the part of the Company to retain you in any capacity, for any period of time or under any specific terms
or conditions, or to continue your service to the Company beyond any period.

 

10.      Governing
Law; Consent to Jurisdiction.  All questions with respect to the construction and/or enforcement of this Agreement, and
the rights and obligations of the parties hereunder, shall be determined in accordance with the laws of the State of California
applicable to agreements made and to be performed entirely in the State of California. The parties hereby consent to the jurisdiction
of the courts having jurisdiction over matters arising in California for any proceeding arising out of or relating to this Agreement.

 

11.
     Entire Agreement; Amendment; Waiver; Counterparts. This Agreement expresses
the entire understanding with respect to the subject matter hereof and supersedes and terminates any prior oral or
written agreements with respect to the subject matter hereof. Any term of this Agreement may be amended and observance of any
term of this Agreement may be waived only with the written consent of the parties hereto. Waiver of any term or condition of
this Agreement by any party shall not be construed as a waiver of any subsequent breach or failure of the same term or
condition or waiver of any other term or condition of this Agreement. The failure of any party at any time to require
performance by any other party of any provision of this Agreement shall not affect the right of any such party to require
future performance of such provision or any other provision of this Agreement. This Agreement may be executed in separate
counterparts each of which will be an original and all of which taken together will constitute one and the same agreement.
This Agreement may be executed using facsimiles of signatures, and a facsimile of a signature shall be deemed to be the same,
and equally enforceable, as an original of such signature.

 

 

[Remainder
of Page Left Blank Intentionally

 

 

 

]

 

 

    	4

    	 

    

 

This Agreement has been executed
and delivered by the undersigned and is made effective as of the date set first set forth above.

 

 

	 	 	Sincerely,
	 	 	 
	 	 	PharmaCyte Biotech, Inc.
	 	 	 
	 	 	 
	 	 	By:                                                                  
	 	 	Name: Kenneth L. Waggoner
	 	 	
        Title:  Chief Executive Officer

                   President and General Counsel

	 	 	 

 

AGREED AND ACCEPTED:

 

/s/ Thomas Liquard                                   

 

Name: Thomas Liquard

 

 

 

 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]